87S Stock Overview
A commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Roivant Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.50 |
| 52 Week High | US$12.11 |
| 52 Week Low | US$8.65 |
| Beta | 1.25 |
| 1 Month Change | -3.58% |
| 3 Month Change | 2.84% |
| 1 Year Change | 14.08% |
| 3 Year Change | 4.95% |
| 5 Year Change | n/a |
| Change since IPO | 91.79% |
Recent News & Updates
Recent updates
Shareholder Returns
| 87S | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.6% | -2.9% | -2.6% |
| 1Y | 14.1% | -14.7% | 6.9% |
Return vs Industry: 87S exceeded the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: 87S exceeded the German Market which returned 6.9% over the past year.
Price Volatility
| 87S volatility | |
|---|---|
| 87S Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 87S's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 87S's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 908 | Matt Gline | roivant.com |
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases.
Roivant Sciences Ltd. Fundamentals Summary
| 87S fundamental statistics | |
|---|---|
| Market cap | €8.07b |
| Earnings (TTM) | €4.40b |
| Revenue (TTM) | €123.76m |
1.8x
P/E Ratio65.2x
P/S RatioIs 87S overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 87S income statement (TTM) | |
|---|---|
| Revenue | US$129.13m |
| Cost of Revenue | US$552.21m |
| Gross Profit | -US$423.08m |
| Other Expenses | -US$5.02b |
| Earnings | US$4.60b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.31 |
| Gross Margin | -327.64% |
| Net Profit Margin | 3,558.52% |
| Debt/Equity Ratio | 0% |
How did 87S perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 04:03 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Roivant Sciences Ltd. is covered by 16 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ishan Majumdar | Baptista Research |
| Chi Meng Fong | BofA Global Research |
| Louise Chen | Cantor Fitzgerald & Co. |